Anti-sortilin antibodies and methods of use thereof

US12297277B2 · kind B2 · utility

Assignee

• Alector LLC

Inventors

• Tina SCHWABE · San Francisco, US
• Michael Kurnellas · San Francisco, US
• Arnon Rosenthal · Woodside, US
• Robert Pejchal · Hartford, US
• Anthony B. Cooper · South San Francisco, US

Key dates

• Filing date: Jun 9, 2022
• Grant date: May 13, 2025
• Expiry date: May 19, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.